日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer

在激素受体阳性/HER2阴性转移性乳腺癌的治疗过程中,制定个性化治疗方案

Singareeka Raghavendra, Akshara; Damodaran, Senthil; Barcenas, Carlos H; Fuqua, Suzanne A; Layman, Rachel M; Tripathy, Debu

SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial

SHR-A1811,一种新型靶向 HER2 的抗体药物偶联物,在晚期实体瘤中的应用(HORIZON-X):一项全球 1 期试验

Yao, Herui; Yan, Min; Tong, Zhongsheng; Wu, Xinhong; Yin, Yongmei; Ryu, Min-Hee; Park, John J; Jiang, Shusuan; Kim, Jee Hyun; Wang, Shouman; Zhong, Yahua; Voskoboynik, Mark; Zhang, Jian; Kaubisch, Andreas; Liu, Caigang; Chen, Yu; Im, Seock-Ah; Wu, Lingying; Liu, Yingbin; Ganju, Vinod; Barve, Minal; Li, Hui; Yao, Guangyu; Yang, Mudan; Bao, Lequn; Zhao, Yiming; Zhao, Jianli; Zhao, Kaijing; Shen, Yu; Rong, Shangyi; Zhu, Xiaoyu; Song, Erwei

HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial)

HDAC抑制剂tucidinostat和节拍式卡培他滨联合内分泌治疗用于CDK4/6抑制剂治疗后HR阳性HER2阴性晚期乳腺癌患者:一项多中心2期研究的临床结果和探索性循环肿瘤细胞和ctDNA生物标志物分析(SYSUCC-020试验)

Wu, Huai-Liang; Xia, Wen; Xu, Zhengyang; Zhou, Hanxing; Chen, Limin; Lu, Yongkui; Liu, Xinlan; Pang, Danmei; Liu, Yan; Lu, Qianyi; Xu, Fei; An, Xin; Huang, Jiajia; Jiang, Kuikui; Zhang, Jingmin; Cai, Yili; Hong, Ruoxi; Zheng, Qiufan; Wang, Shusen

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial

吡咯替尼或安慰剂联合曲妥珠单抗和多西他赛治疗HER2阳性转移性乳腺癌:随机3期PHILA试验的长期生存结果

Ma, Fei; Yan, Min; Li, Wei; Ouyang, Quchang; Tong, Zhongsheng; Teng, Yuee; Wang, Yongsheng; Wang, Shusen; Geng, Cuizhi; Luo, Ting; Zhong, Jincai; Zhang, Qingyuan; Liu, Qiang; Zeng, Xiaohua; Sun, Tao; Mo, Qinguo; Zhou, Shoubing; Li, Peidong; Cheng, Jing; Wang, Xiaojia; Nie, Jianyun; Yang, Jin; Wu, Xinhong; Wang, Xinshuai; Li, Huiping; Yao, Guangyu; Fan, Yang; Lin, Jiaman; Zhu, Xiaoyu; Xu, Binghe

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

VIKTORIA-1试验:Gedatolisib联合Fulvestrant,加或不加Palbociclib治疗激素受体阳性/HER2-/PIK3CA野生型晚期乳腺癌

Hurvitz, Sara A; Layman, Rachel M; Curigliano, Giuseppe; André, Fabrice; Cristofanilli, Massimo; Kim, Sung-Bae; Martínez Rodríguez, Jorge Luis; Nadal, Jorge C; Kim, Gun Min; Lo, Louisa; Remolina-Bonilla, Yuly A; Rosselli, Geronimo; Emile, George; Korbenfeld, Ernesto; Puig, Juan Manuel; Wesolowski, Robert; Martin, Miguel; Ring, Alistair; Han, Hyo S; Giordano, Antonio; Mutka, Sarah C; Moss, Keren; Suzuki, Sam; Sullivan, Brian; Gorbatchevsky, Igor; Pistilli, Barbara

Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

塞伐替尼,一种对肺癌有效的可逆性HER2抑制剂

Siegel, Franziska; Siegel, Stephan; Kotýnková, Kristýna; Karsli Uzunbas, Gizem; Korr, Daniel; Tomono, Haruna; Andersen, Sawyer; Denney, Daniel; Berger, Markus; Schulze, Volker K; Lewis, Timothy A; Kaplan, Bethany; Golfier, Sven; Mortier, Jérémie; Hillig, Roman C; Boemer, Ulf; Petersen, Kirstin; Eis, Knut; Williams, Sybil; Rüttinger, Dominik; Cherniack, Andrew D; Loong, Herbert H; Goto, Koichi; Grassi, Paolo; Meyerson, Matthew; Greulich, Heidi

Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2(+) breast cancer: TBCRC049 phase 2 study results

Tucatinib-trastuzumab-capecitabine治疗HER2(+)乳腺癌女性软脑膜转移:TBCRC049 II期研究结果

Murthy, Rashmi K; O'Brien, Barbara J; Berry, Donald A; Singareeka-Raghavendra, Akshara; Monroe, Maria Gule; Johnson, Jason; White, Jason; Schwartz-Gomez, Jill; Topletz-Erickson, Ariel; Lobbous, Mina; Riley, Kristen; Melisko, Michelle; Morikawa, Aki; Ferguson, Sherise D; de Groot, John F; Krop, Ian E; Valero, Vicente; Rimawi, Mothaffar F; Wolff, Antonio C; Tripathy, Debu; Lin, Nancy U; Stringer-Reasor, Erica M

Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01

Zanidatamab治疗HER2阳性转移性胆道癌:HERIZON-BTC-01研究的最终结果

Pant, Shubham; Fan, Jia; Oh, Do-Youn; Choi, Hye Jin; Kim, Jin Won; Chang, Heung-Moon; Bao, Lequn; Sun, Hui-Chuan; Macarulla, Teresa; Xie, Feng; Metges, Jean-Phillippe; Ying, Jie'er; Bridgewater, John; Lee, Myung-Ah; Tejani, Mohamedtaki A; Chen, Emerson Y; Wasan, Harpreet; Ducreux, Michel; Bao, Yuanyuan; Wu, Xiaotian; Zhao, Yi; Garfin, Phillip M; Gable, Jonathon; Harding, James J

COLEC12high tumor-associated macrophages orchestrate lenvatinib resistance and cancer stemness in hepatocellular carcinoma via paracrine NRG1-HER2/HER3 signaling

COLEC12高表达的肿瘤相关巨噬细胞通过旁分泌NRG1-HER2/HER3信号通路调控肝细胞癌的乐伐替尼耐药性和癌症干细胞特性

Zhang, Jianxing; Qiao, Liang; Wu, Zongfeng; Zuo, Dinglan; Huang, Shanshan; Liu, Shaoru; Huang, Zhenkun; Zeng, Yi; Li, Yu; Yuan, Yichuan; Wang, Chenwei; He, Wei; Qiu, Jiliang; Yuan, Yunfei; Niu, Yi; Li, Binkui

Integrated Multi-omic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer

整合多组学分析鉴定出 BRD8/EP400 是介导 HR+/HER2+ 乳腺癌抗 HER2 反应的关键染色质模块

Gao, Ang; Khatri, Parth H; Ma, Gui; Liu, Peng; Fernandez-Martinez, Aranzazu; Donahue, Kristine; Wang, Yidan; Kim, Eui-Jun; Hu, Mingshan; Liu, Fabao; Zhou, Jingjing; Chan, Ngai Ting; Yang, Xingjian; Welch Schwartz, Rene; Ong, Irene M; Burkard, Mark E; Wisinski, Kari B; Perou, Charles M; Dinh, Huy Q; Xu, Wei